Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.
Novel 1-anilino-4-phenylphthalazine derivatives, compositions containing them, and their use as JAK1 inhibitors and for the treatment of cancer, inflammatory and autoimmune diseases are claimed. This represents a novel scaffold for JAK inhibitors and is highly distinct from the JAK1 inhibitors previously described, although the same scaffold has been employed in other kinase inhibitors.
Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com
Peter
P
Norman
D001327:Autoimmune Diseases / Q000188:drug therapy / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D010330:Patents as Topic; D010793:Phthalazines / Q000737:chemistry / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*
D010793:Phthalazines; D047428:Protein Kinase Inhibitors; D053613:Janus Kinase 1